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Introduction
It is widely accepted that an intact healthy vascular endothelium plays a significant role in maintaining normal blood fluidity by presenting a noncoagulant-nonthrombogenic surface to circulating blood constituents (1, 2) . In the course of studies on fundamental mechanisms of this important cellular function, the endothelial cell surface has recently been shown to remove thrombin, the most important activated coagulation factor, from the circulation and to accelerate the thrombin-antithrombin III reaction (3) (4) (5) (6) (7) . Data obtained in vivo and in vitro have indicated that the rapid inhibition of thrombin requires binding ofthrombin to the high-affinity binding sites on the endothelium (3) (4) (5) , and that the endothelial antithrombin III cofactor has functional properties in common with the anticoagulant glycosaminoglycans, heparin, and heparan sulfate (7) (8) (9) . Glycosaminoglycans such as heparan sulfate have been reported to be surface components of endothelial celis in vitro (10) and in vivo (11) . Thus , it has been postulated that a heparinlike substance present on the endothelial cell surface is responsible for the high-affinity binding of thrombin and catalysis of the thrombin-antithrombin III reaction (2, 12) .
Radiolabeled or unlabeled thrombin has been shown to bind to cultured endothelial cells or intact endothelium (13) (14) (15) (16) (17) (18) . Few studies so far have investigated the role of glycosaminoglycans in these bindings, and those that did employed only indirect methods. These studies have included testing the effects of chemical modifications to the heparin-binding site of thrombin on the binding of thrombin to endothelial cells (18) and the comparison of thrombin binding to vascular endothelium with that of thrombin to artificial surfaces containing glycosaminoglycans such as heparin and heparan sulfate (9) . The data obtained by these techniques, on the one hand, have been consistent with the proposed hypothesis of the binding of thrombin to glycosaminoglycans. On the other hand, interactions of thrombin with endothelium have been demonstrated to result in several other biological effects on these cells (19) , including protein C activation by a complex between thrombin and thrombomodulin, an endothelial cell surface cofactor (20) . A In a previous report, we presented data describing the interaction between lipoprotein lipase and endothelial cells, in which the presence of cell surface glycosaminoglycans was related to the binding of lipoprotein lipase (21) . In the present study, we provide the first direct evidence that cell surface heparan sulfate is, at least in part, also involved in the highaffinity binding of thrombin to endothelial cells.
Methods
Materials. Bovine serum albumin (essentially fatty acid-free), protamine sulfate, chondroitin sulfate (mixed isomers), trypsin, and glucose without phenol red, Dulbecco's phosphate-buffered saline, and fetal calf serum were obtained from Grand Island Biological Co., Grand Island, NY. Petri dishes (35 X 10 mm) were products of Falcon Labware, Cockeysville, MD. Diisopropylfluorophosphate (DFP)' was obtained from Fluka AG, Buchs, Switzerland. Tosyl-glycine-prolinearginine-p-nitroanilide was obtained from Pentapharm Ltd., Basel, Switzerland. Na'25I (17 22 mCi/ml) was obtained from the Japanese Atomic Energy Research Institute, Ibaragi, Japan. Bovine fibrinogen with a coagulability of 98% was purchased from Daiichi Kagaku, Tokyo. Pronase was obtained from Kaken Chemicals Co., Tokyo. Dispase was a product of Godo Shusei Co., Tokyo. Heparitinase and chondroitin ABC lyase was obtained from Seikagaku Kogyo, Tokyo. Crude Flavobacterium heparinum enzyme prepared from F. heparinum (22) was provided by Dr. T. Okuyama, Tokyo. Captopril was a generous gift from Sankyo Co., Tokyo. All other materials were reagent grade.
Endothelial cell cultures. Aortic endothelial cells were isolated from the descending thoracic aorta from pigs immediately after death, and were cultured as previously described (21), with minor modifications. Aorta segments 10 cm in length were drained of excess Dulbecco's phosphate-buffered saline containing antibiotics (100 U/ml penicillin, 100 ug/ml streptomycin, and 1.25 Ag/ml amphotericin B). The intercostal arteries were closed with clamps, and one end was closed with a hemostat. The aorta was then filled with 5-10 ml of Dispase (1,000-2,000 U/ml) in RPMI-1640 medium containing 5% calf serum, and incubated for 15-20 min at 370C. The Dispase solution was collected and the lumen of the vessels was rinsed once with cold phosphatebuffered saline. These fractions were pooled, and further phosphatebuffered saline was added so that the concentration of Dispase was finally diluted fivefold. The cells were sedimented at 160 g for 6 min at 4°C, and placed into 35-mm petri dishes containing RPMI-1640 medium supplemented with 10% fetal calf serum and antibiotics as above. These cultures were incubated at 37°C in a humidified atmosphere of 5% CO2 in air for -7 d before use at subconfluence. Only primary cultures of endothelial cells were used.
Characterization of the primary cultures showed the typical microscopic cobblestone appearance of endothelial cells and contact inhibition in monolayer culture. To confirm the identity of cultured endothelial cells, angiotensin-converting enzyme activity was measured in the cell homogenates according to the colorimetric method described by Kasahara and Ashihara (23) . The enzymatic activity that could be inhibited by 2 ,M of captopril was 182±59 nmol histidyl-leucine per mg of cell protein per h (mean±SE of 15 determinations), whereas essentially no activity was found in cultured subendothelial cells of several passages.
Thrombin preparations. Bovine a-thrombin was a generous gift from Dr. T. Morita, Department of Biology, Kyushu University, Fukuoka, Japan and was prepared as previously described (24) . It was essentially homogenous as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (25) Lowry et al. (27) .
In some experiments, thrombin binding was also measured with its enzymatic activity. Unlabeled purified thrombin was incubated for 10 min with the washed endothelial cell cultures in 0.5 ml of Hanks' balanced salt solution containing bovine serum albumin (1 mg/ml) at 37°C. The incubation media were collected and maintained at 4°C before assay for unbound thrombin activity. After the cell layer was rinsed three times with iced Hanks' balanced salt solution, 0.5 ml of this solution containing bovine serum albumin was added and the cells were scraped with a rubber policeman. The cell suspension was sonicated for 10 s at 4°C. Amidolytic activities of thrombin in the incubation media and in the cell homogenates were determined using the chromogenic substrate as previously described (26) . The mixture of enzyme and the substrate was incubated at 37°C long enough to yield 0.1 < A405 (usually for 3 min). The readings of absorbance were repeated every minute during incubations.
Treatment of endothelial cell cultures with glycosaminoglycandegrading enzymes. Enzyme activities of the crude F. heparinum enzyme preparation, purified heparitinase, and chondroitin ABC lyase were measured by increase in A232 due to an unsaturated double bond introduced during cleavage between the hexosamines and uronic acids with heparin, heparan sulfate, and chondroitin sulfate, respectively, as substrate. This activity was expressed as micromoles of unsaturated double bond appearing from each substrate per hour (21) . The crude F. heparinum enzyme preparation contains chondroitin lyase, dermatanase, heparinase, and heparitinase activities. Purified heparitinase has essentially no activity on chondroitin sulfate, dermatan sulfate, or heparin (< 0.2% of heparitinase activity).
Washed endothelial cell cultures were incubated for 60 min at 370C in 0.15 ml of Hanks' balanced salt solution with (a) 1.6 U/ml of crude F. heparinum enzyme, (b) 0.6 U/ml of heparitinase, (c with cells for 24 or for 42 h, respectively. After removal of the medium and washing with Hanks' balanced salt solution 10 times, the cell layers were incubated for 60 min at 37°C with 0.15 ml of Hanks' balanced salt solution containing either crude F. heparinum enzyme, heparitinase, or chondroitin ABC lyase as above. Each of the solutions was removed to provide an "enzyme" fraction, and cultures were then incubated with 0.5 ml of 0.25% trypsin to lift the cells from the plates. The cell suspensions were centrifuged to obtain a supernate ("trypsinate" fraction) and a cell pellet ("cell" fraction). The trypsinate fraction includes glycosaminoglycans or proteins derived from the cell surface and from the solubilized matrix (28) . The cultures were then treated with 0.5 ml of 0.1 N NaOH for removal of radioactivity remaining on the plates ("plate" fraction). The 35S-labeled glycosaminoglycans in "trypsinate" fractions were isolated by modifications of the methods described by Wasteson et al. (29) as follows: pronase (1 mg) was added to 0.4 ml of "trypsinate" fraction from each dish. Proteolysis was continued for 3 h at 37°C. For chondroitin ABC lyase treatments, aliquots of pronase digests were boiled for 15 min, and after being cooled, were treated with 15 U/ml of chondroitin ABC lyase for 4 h at 37°C (30) . Pronase digests, before or after treatments with chondroitin ABC lyase, were mixed with 0.1 ml of 0.2 M NaCl containing 2 mg of carrier chondroitin sulfate and 0.5 ml of 1% cetylpyridinium chloride. After incubation at 37°C for 1 h, the precipitate was collected by centrifugation at 2,000 g for 30 min. The cetylpyridinium-glycosaminoglycan complex was dissolved in 0.1 ml of 4 M NaCl and reprecipitated with 1.4 ml of 80% aqueous ethanol to obtain purified glycosaminoglycans. These were dissolved in 0. (32) . The slabs, after they were stained with Coomassie Blue, were dried down onto paper, and autoradiographs were made on x-ray film (X-OMAT AR; Eastman Kodak Co., Rochester, NY).
Results
Binding ofthrombin to endothelial cells. A time course of 125I-thrombin binding to the surface of endothelial cell monolayers is shown in Fig. 1 (0 (Fig. 3) or heparitinase (Fig. 4) was significantly less at each thrombin concentration than that bin. See the legend to Fig. 3 for further details. t P < 0.06 (onetailed t test). On the other hand, after treatment of cells with chondroitin ABC lyase, at each thrombin concentration, the amount of thrombin specifically bound was not different from that after treatment with Hanks' balanced salt solution alone (Fig. 5) .
In the next experiment, '25I-thrombin binding to the endothelial cell surface was carried out in the presence of 10 ,ug/ ml of protamine sulfate. As shown in Fig. 6 (inset) , 12511 thrombin bound to endothelial cell surface specifically and nonspecifically was significantly reduced to 35 and 68% of that in the absence of protamine sulfate, respectively, and at each thrombin concentration, thrombin specifically bound to the cells in the presence of protamine sulfate was considerably less, by 45-67%, than that in the absence of this compound (Fig. 6) . When the protamine concentration was increased from 10 to 100 ,ug/ml, the same results were obtained.
Previously two independent types of binding of thrombin to endothelial cells were demonstrated (14) . One type was rapid, reversible, and active site-independent, whereas the other was slow, irreversible, and active site-specific. Thrombin binding to endothelial cells after treatment with heparitinase was characterized in these respects in comparison with that after treatment with Hanks' balanced salt solution alone. Table  I shows that specific thrombin binding to endothelial cells was completely displaced by an excess amount of inactive thrombin and was, highly reversible. These characteristics were not changed after heparitinase treatments.
A time course of initial rapid binding of thrombin to the endothelial cells after treatment with heparitinase was also compared with that of thrombin binding to the cells without Effects of glycosaminoglycan-degrading enzyme treatment on the endothelial cell surface glycosaminoglycans. Table II shows the effects of various glycosaminoglycan-degrading enzyme treatments on 35S-labeled compounds in various fractions of endothelial cells. More 35S-compounds were released into the medium (enzyme fraction) by all these enzymatic treatments than from the cells treated with Hanks' balanced salt solution alone. The order of the potential for release was crude F. heparinum enzyme > heparitinase > chondroitin ABC lyase.
[35S]glycosaminoglycans remaining on the cell surface after these enzymatic treatments Effects of glycosaminoglycan-degrading enzyme treatment on the endothelial cell surface proteins. The potential presence of contaminating protease activity in these glycosaminoglycan lyase preparations was examined in two different ways. As shown in Table III , when endothelial cells were labeled with [3H]leucine, a slight but significant increase in the release of 3H-labeled compounds by crude F. heparinum enzyme treatment was observed compared with the release by the treatment with Hanks' balanced salt solution alone. On the other hand, release of 3H by heparitinase or chondroitin ABC lyase treatment was not different from that by treatment with Hanks' balanced salt solution alone. When trichloroacetic acid-precipitable counts were determined, essentially the same results were obtained (data not shown).
Because [3H]leucine will label all of the endothelial cell proteins and only minor portions of these proteins are located on the cell surface, the data might be inadequate to exclude proteolysis of cell surface proteins. Therefore, in the next experiment, the cell surface proteins were specifically labeled with 125I and the effects of glycosaminoglycan-degrading enzyme treatment on these 1251-labeled proteins were tested. As shown in Table IV f3-galactosidase (1 16 ,000 mol wt), phosphorylase a (94,000 mol wt), bovine serum albumin (68,000 mol wt), glutamate dehydrogenase (53,000 mol wt), ovalbumin (43,000 mol wt). K, molecular weight: e.g., 1 16K = 1 6,000 mol wt. It has been speculated that a heparin-like substance present on the endothelial cell surface is responsible for the anticoagulant property of the endothelium (2, 12) . In fact, some evidence in support of this concept has appeared. This evidence includes direct or indirect characterizations of anticoagulant activity of heparin-like species on endothelium (8, 9, 33, 34) . Lollar and Owen (3) and Busch and Owen (8) have proposed that the inactivation of thrombin by antithrombin III is catalyzed by the active site-independent high-affinity binding sites on the endothelial cell surface, based on their series of experiments that used in vivo and in vitro cell culture preparations. The present finding has provided the first direct evidence that heparan sulfate on the endothelial cell surface is indeed involved in the high-affinity, active site-independent thrombin binding by these cells. In the most recent report, by perfusing rat hindlimb preparations with purified thrombin and with antithrombin, Marcum et al. (35) have found that the vascular endothelium can accelerate thrombin-antithrombin interactions, and that heparinlike substances are responsible for this activity. Furthermore, they have concluded that thrombin bound to the endothelium, as well as enzyme free in solution, are neutralized by "activated" antithrombin, inasmuch as inhibition of thrombin binding to the endothelium by addition of DIP-thrombin to the system reduced the amount of thrombin-antithrombin complex formed by 30-40%. On the other hand, using recirculating Langendroff preparations with purified reagents, Lollar et al. (36) found that binding of thrombin to the sites on the microvascular endothelium had no effect on the reaction of the enzyme with antithrombin III. Thus, whether heparan sulfate responsible for thrombin binding observed in the present study is related to the anticoagulant activity such as cofactor for antithrombin III on endothelium, as has been postulated, is yet to be determined. Alternatively, if bound thrombin is less active than free enzyme toward procoagulant substrates such as fibrinogen, thrombin clearance by the endothelium in itself would serve an anticoagulant role in hemostasis. Buonassisi et al. (37) Also note that the present findings are confined to the in vitro system using cell culture and defined reagents. In plasma, there are much greater amounts of several other heparinbinding proteins including a potent heparin antagonist, histidine-rich glycoprotein (38) , and heparin cofactor, antithrombin III (35) . Therefore, what, and to what extent, is bound to heparin-like species on the vascular endothelial cell surface in vivo is yet to be clarified.
